Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).
저자
Park, In Hae; Kim, Gun Min; Kim, Jee Hyun; Kim, Hanjo; Park, Kyong Hwa; Park, Yeon Hee; Baek, Sun Kyung; Sim, Sung Hoon; Ahn, Hee Kyung; Lee, Gyeong-Won; Lee, Kyoung Eun; Lee, Ji Eun; Lim, Seungtaek; Jung, Kyung Hae; Im, Seock-Ah